Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis
Cendakimab demonstrated statistically significant improvements in symptoms, histologic response, and endoscopic features of EoE versus placebo; the adverse-event and side-effect profile was not dose limiting. (Funded by Bristol Myers Squibb; ClinicalTrials.gov number, NCT04753697.).
Authors
- Jesse Siffledeen
- Hamish Philpott (ORCID: https://orcid.org/0000-0002-1973-6355)
- Evan S. Dellon (ORCID: https://orcid.org/0000-0003-1167-1101)
- Carla L. Zema
- Ashwini Venkatasamy
- Alain Schoepfer
- Yasuhiko Abe (ORCID: https://orcid.org/0000-0002-5337-4802)
- Christopher Ma (ORCID: https://orcid.org/0000-0002-4698-9948)
- Kexuan Li (ORCID: https://orcid.org/0000-0001-5343-7570)
- Gary W. Falk (ORCID: https://orcid.org/0000-0002-7143-1436)
- Christina M. Charriez
- Shauna Schroeder
- Sandra Zhang
- Salvatore Oliva (ORCID: https://orcid.org/0000-0003-2348-2308)
- Tim Vanuytsel (ORCID: https://orcid.org/0000-0001-8728-0903)
- Anusha K. Yeshokumar (ORCID: https://orcid.org/0000-0001-6867-3947)
- Young S. Oh (ORCID: https://orcid.org/0000-0001-8187-2588)
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Alberta (CA)
- University of Calgary (CA)
- Policlinico Umberto I (IT)
- Lyell McEwin Hospital (AU)
- Centre Hospitalier Universitaire Vaudois (CH)
- University of Alberta Hospital (CA)
- Bristol-Myers Squibb (United States) (US)
- Phoenix Children's Hospital (US)
- Yamagata University Hospital (JP)
- University of Pennsylvania (US)
- University of Lausanne (CH)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1056/evidoa2500095
- Citations
- 7
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 14.04